retosiban + efavirenz

**Retosiban + efavirenz** is a hypothetical or investigational combination drug consisting of **retosiban** (an oral, selective oxytocin receptor antagonist, originally developed for preterm labor) and **efavirenz** (a non-nucleoside reverse transcriptase inhibitor approved for the treatment of HIV-1 infection)[5]. Retosiban acts by blocking the oxytocin receptor, thereby inhibiting uterine contractions, while efavirenz inhibits HIV reverse transcriptase, interfering with viral replication. There is no evidence from current regulatory or clinical sources that this combination has been clinically developed, approved, or marketed as a fixed product. The combination would contain two small molecules with fundamentally distinct mechanisms and indications.